Watmind USA™ Secures FDA Emergency Use Authorization for 15-Minute At-Home SpeedySwab™ Test for COVID-19, Flu A, and Flu B

Saturday, June 01, 2024

Watmind USA™, a leading provider of health diagnostic testing solutions, is excited to announce that it has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its SpeedySwab™ Covid + FLU A&B Self-Test.

This test is approved for over-the-counter (OTC) and point-of-care (POC) use, offering a quick and reliable at-home solution for detecting COVID-19, Influenza A, and Influenza B simultaneously.

Developed in collaboration with the National Institutes of Health's Rapid Acceleration of Diagnostics (RADx) Independent Test Assessment Program (ITAP), the SpeedySwab™ aims to transform home diagnostics.

The SpeedySwab™ OTC test is designed for symptomatic individuals aged 2 and older, allowing them to quickly identify if their symptoms are due to COVID-19, Influenza A, or Influenza B.

The test employs advanced Lateral Flow Assay (LFA) technology and provides a straightforward, step-by-step process. This affordable solution is crucial as it helps distinguish between these viruses, which often present with similar symptoms.

"Receiving the EUA for our SpeedySwab™ test is a significant achievement in our efforts to improve public health".

"In the face of ongoing challenges posed by COVID-19 and influenza A&B strains, our aim is to offer accessible and rapid at-home testing solutions.

These solutions empower individuals to manage their health from home and help reduce the spread of these diseases. Watmind USA™ is committed to supporting essential public health initiatives."


Harvard Medical School - Leadership in Medicine Southeast Asia47th IHF World Hospital Congress